Summary of COVID-19 hypochlorous acid studies
1. Gutiérrez-García et al., Nasopharyngeal and oropharyngeal rinses with neutral electrolyzed water prevents COVID‑19 in front‑line health professionals: A randomized, open‑label, controlled trial in a general hospital in Mexico City
163 patient hypochlorous acid prophylaxis RCT: 91% fewer symptomatic cases (p=0.004).RCT 170 front-line healthcare workers in Mexico showing significantly lower COVID-19 cases with neutral electrolyzed water (SES) nasal and oral rinses. Authors hypothesize that SES inactivates viral particles through its oxidizing potential, reducing viral load in the upper respiratory tract where SARS-CoV-2 initially establishes infection. HOCl is the primary active component of neutral electrolyzed saline.
Dec 2021, Biomedical Reports, http://www.spandidos-publications.com/10.3892/br.2021.1494, https://c19p.org/gutierrezgarcia
2. Delgado-Enciso et al., Safety and efficacy of a COVID‑19 treatment with nebulized and/or intravenous neutral electrolyzed saline combined with usual medical care vs. usual medical care alone: A randomized, open‑label, controlled trial
139 patient hypochlorous acid early treatment RCT: 28% improved recovery (p<0.0001).RCT 214 ambulatory COVID-19 patients showing significant benefit with nebulized and/or intravenous neutral electrolyzed saline. The treatment group had reduced risk of hospitalization, lower mortality, and faster time to an acceptable symptom state. The benefit was most pronounced in moderate/severe patients. HOCl is the primary active component of neutral electrolyzed saline. This study includes nebulized and IV use which have different mechanisms of action. Nebulized treatment directly destroys the viral lipid envelope, whereas IV use may be beneficial via immunomodulation to minimize cytokine storm. For meta-analysis, we currently only include nebulized treatment. In this study, the only results provided for patients receiving nebulized treatment only is the change in symptom severity shown in Figure 2.
Jun 2021, Experimental and Therapeutic Medicine, http://www.spandidos-publications.com/10.3892/etm.2021.10347, https://c19p.org/delgadoenciso
57 patient hypochlorous acid early treatment RCT: 29% improved viral clearance (p=0.01).
RCT 57 mild COVID-19 patients showing non-significant viral load reduction with Sentinox (STX), a hypochlorous acid nasal spray. The proportion of COVID negative patients by day 5 was significantly higher in the STX-3 group than controls. Authors note that the results were likely driven by outliers with extreme baseline viral loads. When considering subjects with baseline cycle threshold values of 20-30, STX-3 showed a significant 2.01 log10 reduction. A complementary in vitro study demonstrated STX had ≥99.9% virucidal activity against various respiratory viruses including influenza, RSV, rhinovirus, adenovirus, parainfluenza, and seasonal coronavirus.
May 2022, Viruses, https://www.mdpi.com/1999-4915/14/5/1033, https://c19p.org/panattohocl